IMC-F106C
PRAME-positive Solid Tumors (e.g., NSCLC, Endometrial, Ovarian, Breast)
Phase 3Active
Key Facts
Indication
PRAME-positive Solid Tumors (e.g., NSCLC, Endometrial, Ovarian, Breast)
Phase
Phase 3
Status
Active
Company
About Immunocore
Immunocore is a UK-based, publicly traded biotech focused on developing transformative T cell receptor-based immunotherapies. Its core achievement is the 2022 launch of KIMMTRAK (tebentafusp), the first-ever approved TCR therapy, for metastatic uveal melanoma. The company is advancing a broad pipeline of bispecific candidates across oncology, virology (HBV, HIV), and autoimmunity using its modular ImmTAX platform, positioning it as a leader in next-generation targeted immunomodulation.
View full company profile